{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:03:23Z","timestamp":1789419803291,"version":"build-2803163510"},"reference-count":26,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T00:00:00Z","timestamp":1141948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patients who were assigned to receive it.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Docetaxel was given at a dose of 125 mg\/m<jats:sup>2<\/jats:sup> once every 21 days as a 1\u2010hour intravenous infusion for a maximum of 12 courses. From January 1997 to November 2001, 109 male patients and 68 female patients (total, 177 patients) were enrolled, and 173 patients were eligible. The median patient age at entry was 13 years (range, 1\u201027 yrs). One hundred sixty patients were evaluable for response.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>There were no deaths attributable to study drug. Hematologic toxicity was common during therapy. Dermatologic, neurologic, pulmonary, and infectious side effects as well as edema were significant. One patient each had acute myeloid leukemia, acute lymphoid leukemia, and high\u2010grade glioma reported as secondary malignancies. One patient with osteosarcoma and 1 patient with rhabdomyosarcoma achieved a complete response. Partial responses were observed in patients with Ewing sarcoma (3 patients), osteosarcoma (1 patient), squamous cell carcinoma (1 patient), and medulloblastoma (1 patient). Seventeen patients had stable disease. The 1\u2010year and 5\u2010year overall survival rates for the 160 evaluable patients were 24% (standard error = 4%) and 6% (standard error = 2%), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Docetaxel demonstrated activity in patients with recurrent Ewing sarcoma but was found to be ineffective for treating the other types of recurrent solid tumors that were studied. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21779","type":"journal-article","created":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T11:47:06Z","timestamp":1141991226000},"page":"1821-1828","source":"Crossref","is-referenced-by-count":56,"title":["Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors"],"prefix":"10.1002","volume":"106","author":[{"given":"Ted","family":"Zwerdling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Krailo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Monteleone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Dunaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nita","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengjia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Reaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,10]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"1","volume-title":"Principles and practice of pediatric oncology","author":"Smith MA","year":"2002"},{"key":"e_1_2_5_3_2","first-page":"4845","article-title":"Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol analogue","volume":"51","author":"Bissery M\u2010C","year":"1991","journal-title":"Cancer Res."},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.4.288"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568011033482422"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1538"},{"key":"e_1_2_5_7_2","first-page":"733","article-title":"Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial","volume":"5","author":"Seibel NL","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.7.1458"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg202"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:20:1:7"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1159\/000086975"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_5_13_2","volume-title":"Guidelines for reporting of adverse drug reactions","author":"National Cancer Institute","year":"1988"},{"key":"e_1_2_5_14_2","volume-title":"The statistical analysis of failure time data","author":"Kalbfleisch JD","year":"1980"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/73.1.13"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1182\/blood.V87.5.1912.1912","article-title":"Distribution of 11q23 Breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment\u2010related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites","volume":"87","author":"Strissel Broeker PL","year":"1996","journal-title":"Blood."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025513106330"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1025436307913"},{"key":"e_1_2_5_19_2","first-page":"3","article-title":"Mechanisms of action of taxanes in prostate cancer","volume":"26","author":"Stein CA","year":"1999","journal-title":"Semin Oncol."},{"key":"e_1_2_5_20_2","first-page":"646","article-title":"Taxol: the first of the taxanes, an important new class of antitumor agents","volume":"19","author":"Rowinsky EK","year":"1992","journal-title":"Semin Oncol."},{"key":"e_1_2_5_21_2","first-page":"2598","article-title":"Role of intestinal P\u2010glycoprotein in the plasma and fecal disposition of docetaxel in humans","volume":"6","author":"van Zuylen L","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-002-0405-9"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.01052.2003"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.050"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200207000-00004"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800100317"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.02.016"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21779","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:45:19Z","timestamp":1760273119000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21779"}},"subtitle":["A report from the Children's Oncology Group"],"short-title":[],"issued":{"date-parts":[[2006,3,10]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,4,15]]}},"alternative-id":["10.1002\/cncr.21779"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21779","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,10]]}}}